Back to Search
Start Over
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- Source :
- The Lancet Oncology. 24:496-508
- Publication Year :
- 2023
- Publisher :
- Elsevier BV, 2023.
- Subjects :
- Oncology
Subjects
Details
- ISSN :
- 14702045
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- The Lancet Oncology
- Accession number :
- edsair.doi...........7adfd2ad44d4d2c2a9c7ef887cf177ac
- Full Text :
- https://doi.org/10.1016/s1470-2045(23)00150-x